Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Products under Development by Stage of Development | 8 | 1 |
| Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Products under Development by Therapy Area | 9 | 1 |
| Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Products under Development by Indication | 10 | 1 |
| Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Pipeline Products Glance | 11 | 1 |
| Early Stage Products | 11 | 1 |
| Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Products under Development by Companies | 12 | 2 |
| Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Products under Development by Universities/Institutes | 14 | 2 |
| Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Therapeutics Assessment | 16 | 7 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 2 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Companies Involved in Therapeutics Development | 23 | 6 |
| AstraZeneca Plc | 23 | 1 |
| Neurimmune Holding AG | 24 | 1 |
| Nordic Bioscience A/S | 25 | 1 |
| Novo Nordisk A/S | 26 | 1 |
| reMYND NV | 27 | 1 |
| Zealand Pharma A/S | 28 | 1 |
| Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Drug Profiles | 29 | 14 |
| (insulin human + pramlintide acetate) Drug Profile | 29 | 1 |
| AM-833 Drug Profile | 30 | 1 |
| KBP-042 Drug Profile | 31 | 2 |
| KBP-056 Drug Profile | 33 | 1 |
| NI-203 Drug Profile | 34 | 1 |
| ReS-13I Drug Profile | 35 | 1 |
| ReS-39I Drug Profile | 36 | 1 |
| Salmon Calcitonin Drug Profile | 37 | 2 |
| Synthetic Peptides to Target IAPP for Obesity and Diabetes Drug Profile | 39 | 1 |
| UGP-302 Drug Profile | 40 | 2 |
| ZP-4982 Drug Profile | 42 | 1 |
| Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Dormant Projects | 43 | 1 |
| Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Discontinued Products | 44 | 1 |
| Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Featured News &Press Releases | 45 | 3 |
| Jun 08, 2016: Zealand presents new data on proprietary preclinical peptide drug candidates at the 76th Annual American Diabetes Associations Scientific Sessions | 45 | 1 |
| May 05, 2014: reMYND s novel diabetes treatment prevents and even reverses disease progression in pre-clinical diabetes models | 45 | 1 |
| Aug 15, 2012: Unigene Labs And Nordic Bioscience Announce Preliminary Selection Of Lead Compound For Treatment Of Type 2 Diabetes | 46 | 2 |
| Appendix | 48 | 2 |
| Methodology | 48 | 1 |
| Coverage | 48 | 1 |
| Secondary Research | 48 | 1 |
| Primary Research | 48 | 1 |
| Expert Panel Validation | 48 | 1 |
| Contact Us | 48 | 1 |
| Disclaimer | 49 | 1 |